Chinese Medical Sciences Journal ›› 2022, Vol. 37 ›› Issue (3): 275-281.doi: 10.24920/003936

• 综述 • 上一篇    下一篇

去甲乌药碱:一种潜在的冠心病诊断心肌负荷药物

张娜娜1,李子健2,*(),朱海波3,*()   

  1. 1中国农业科学院农产品加工研究所,北京100091,中国
    2北京大学第三医院心内科、血管医学研究所,卫生部心血管分子生物学与调节肽重点实验室,分子心血管学教育部重点实验室,心血管受体研究北京市重点实验室,北京100191,中国
    3中国医学科学院北京协和医学药物研究所,天然药物活性物质与功能国家重点实验室新药作用机制研究与药效学评价北京重点实验室,北京100007,中国
  • 收稿日期:2021-05-16 接受日期:2022-01-23 出版日期:2022-09-30 发布日期:2022-06-26
  • 通讯作者: 李子健,朱海波 E-mail:lizijian@bjmu.edu.cn;zhuhaibo@imm.ac.cn

Higenamine as a Potential Pharmacologic Stress Agent in the Detection of Coronary Artery Disease

Nana Zhang1,Zijian Li2,*(),Haibo Zhu3,*()   

  1. 1Institute of Food Science and Technology, Chinese Academy of Agricultural Sciences, Beijing 100050, China
    2Institute of Vascular Medicine, Peking University Third Hospital, Key Laboratory of Cardiovascular Molecular Biology and Regulatory Peptides Ministry of Health, Key Laboratory of Molecular Cardiovascular Sciences Ministry of Education, and Beijing Key Laboratory of Cardiovascular Receptors Research, Beijing 100050, China
    3State Key Laboratory for Bioactive Substances and Functions of Natural Medicines, Beijing Key Laboratory of New Drug Mechanisms and Pharmacological Evaluation Study, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China
  • Received:2021-05-16 Accepted:2022-01-23 Published:2022-09-30 Online:2022-06-26
  • Contact: Zijian Li,Haibo Zhu E-mail:lizijian@bjmu.edu.cn;zhuhaibo@imm.ac.cn

摘要:

心肌灌注显像在冠心病的诊断、预后和管理中具有重要价值。当前,血管扩张剂和肾上腺素剂是最常见的心肌负荷药物。然而,这些药物在部分病人中的应用有限制,并且有多种副反应。因而,有必要开发可以在更多病人中应用的心肌负荷药物。去甲乌药碱是一种β受体激动剂,被批准作为心肌负荷药物应用于心肌缺血的诊断。因其正性肌力作用,去甲乌药碱有望成为用于冠心病诊断的心肌灌注显像负荷药物。本综述总结了去甲乌药碱在心肌灌注显像中的应用,包括其作用机制、给药方式、有效性及安全性。

关键词: 去甲乌药碱, 心肌灌注显像, 负荷药物, 冠状动脉疾病

Abstract:

Myocardial perfusion imaging (MPI) is valuable for the diagnosis, prognosis, and management of coronary artery disease (CAD). The most commonly used pharmacologic stress agents at present are vasodilators and adrenergic agents. However, these agents have contraindications and may cause adverse effects in some patients. Thus, other stress agents feasible for more patients are required. Higenamine (HG) is a β-adrenergic receptor agonist currently approved for clinical trials as a stress agent for myocardial infarction. It also has a promising value in MPI for the detection of CAD in preclinical and clinical studies. This review summarizes the application of HG on MPI, including its mechanism of action, stress protocol, efficacy, and safety.

Key words: coronary artery disease, higenamine, myocardial perfusion imaging, stress agent

基金资助: 中国医学科学院医学与健康科技创新工程(2021-1-I2M-028)

Copyright © 2018 Chinese Academy of Medical Sciences. All right reserved.
 
www.cmsj.cams.cn
京公安备110402430088 京ICP备06002729号-1  Powered by Magtech.

Supervised by National Health Commission of the People's Republic of China

9 Dongdan Santiao, Dongcheng district, Beijing, 100730 China

Tel: 86-10-65105897  Fax:86-10-65133074 

E-mail: cmsj@cams.cn  www.cmsj.cams.cn

Copyright © 2018 Chinese Academy of Medical Sciences

All right reserved.

京公安备110402430088  京ICP备06002729号-1